Skip to main content
. 2020 Sep 2;104(11-12):914–922. doi: 10.1159/000510135

Table 1.

Patient characteristics

Characteristic All Surgeon 1 Surgeon 2 Surgeon 3 p value
Patients, n 594 181 275 138
Patient age, mean (SD), years 70.9 (8.4) 71.2 (8.2) 71.1 (8.4) 69.8 (8.7) 0.204
ASA score, n (%)
 I 41 (6.9) 17 (9.4) 15 (5.5) 9 (6.5) 0.411
 II 333 (56.1) 98 (54.1) 157 (57.1) 78 (56.5)  
 III 212 (35.7) 64 (35.4) 97 (35.3) 51 (37.0)  
 IV 8 (1.3) 2 (1.1) 6 (2.2) 0 (0)  
Preoperative indwelling catheter, n (%)
 None 389 (65.5) 117 (64.6) 180 (65.5) 92 (66.7) 0.825
 Transurethral 169 (28.5) 50 (27.6) 81 (29.5) 38 (27.5)  
 Suprapubic 36 (6.0) 14 (7.7) 14 (5.1) 8 (5.8)  
Preoperative UTI, n (%)
 Yes 202 (34.0) 71 (39.2) 94 (34.2) 37 (26.8) 0.068
 No 392 (66.0) 110 (60.8) 181 (65.8) 101 (73.2)  
Anticoagulation/antiplatelet Tx, n (%)
 Yes 222 (37.4) 62 (34.3) 109 (39.6) 51 (37.0) 0.506
 No 372 (62.6) 119 (65.7) 166 (60.4) 87 (63.0)  
Preoperative prostate volume, median (IQR), cc 85.0 (44.0) 93.0 (43.0) 80.0 (45.0) 75.0 (40.0) <0.001
Preoperative total PSA, median (IQR), ng/mL 4.86 (5.84) 5.31 (5.50) 4.73 (5.62) 4.22 (6.80) 0.212
Any previous prostate biopsy, n (%)
 Yes 164 (27.6) 47 (26.0) 75 (27.3) 42 (30.4) 0.667
 No 430 (72.4) 134 (74.0) 200 (72.7) 96 (69.6)  
Prostate biopsy within 8 weeks before HoLEP, n (%)
 Yes 61 (10.3) 19 (10.5) 28 (10.2) 14 (10.1) 0.993
 No 533 (89.7) 162 (89.5) 247 (89.8) 124 (89.9)  
Preoperative known prostate cancer, n (%)
 Yes 25 (4.2) 4 (2.2) 6 (2.2) 15 (10.9) <0.001
 No 569 (95.8) 177 (97.8) 269 (97.8) 123 (89.1)  

Bold values indicate p values <0.05. UTI, urinary tract infection; Tx, therapy; PSA, prostate-specific antigen; HoLEP, holmium laser enucleation of the prostate; ASA, American Society of Anesthesiologists.